At RSNA 2023 in Chicago, Dr. Busch presented on the retrospective analysis of MRI-guided transurethral ultrasound ablation (TULSA) in prostate cancer lesions at the extreme apex.
The clinical findings show TULSA is a promising prostate cancer treatment with minimal impact on urinary continence for thermal ablation of extreme apical lesions.
With a prostatectomy, the urologist is unable to see the difference between the apex of the prostate and the external sphincter. If a patient has an apical lesion and it is too close to the external sphincter, two things can happen:
- The urologist cuts out too much of the apex and the external sphincter and patients will chronically leak urine. The patient will have to wear a pad or a diaper and may need surgery to insert an artificial sphincter in an attempt to stop the constant urine flow.
- The urologist cuts across the tumor margin and leaves tumor behind, resulting in the man having to have radiation six weeks after his prostatectomy. 50% of these men will leak urine and can get a urethral stricture from the radiation.
Read the full paper to learn more about why TULSA Procedure is a safer, more effective alternative to prostatectomy surgery and other prostate cancer treatments.
Busch Center is proud to be the #1 private clinic in North America, and #2 in the world, offering the TULSA Procedure for treating prostate cancer and BPH.